Search Results - "Tolentino, Michael"

Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease by Tolentino, Michael, MD

“…Abstract The treatment of ocular neovascular diseases is being revolutionized by intravitreal therapies targeting vascular endothelial growth factor (VEGF)…”
Get full text

Drugs in Phase II clinical trials for the treatment of age-related macular degeneration by Tolentino, Michael John, Dennrick, Abrahan, John, Elizabeth, Tolentino, Michael Steven

“…The clinical development of anti-VEGF therapies for the treatment of exudative age-related macular degeneration (wet AMD) has revolutionized ophthalmology…”
Get more information

Current and investigational drugs for the treatment of diabetic retinopathy by Tolentino, Michael Steven, Tolentino, Andrew John, Tolentino, Michael John

“…Diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) are the two complications of diabetes that cause visual loss and blindness. Laser…”
Get more information

Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial by Dugel, Pravin U., MD, Tolentino, Michael, MD, Feiner, Leonard, MD, PhD, Kozma, Petra, MD, PhD, Leroy, Annick, PhD

“…Purpose The Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) trial was designed to evaluate the long-term…”
Get full text

Current molecular understanding and future treatment strategies for pathologic ocular neovascularization by Tolentino, Michael J

“…The leading cause of blindness in the developed world results from several disorders that have pathologic ocular neovascularization as the common pathway…”
Get more information

Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular Edema by Campochiaro, Peter A., MD, Brown, David M., MD, Pearson, Andrew, MD, Ciulla, Thomas, MD, Boyer, David, MD, Holz, Frank G., MD, Tolentino, Michael, MD, Gupta, Amod, MD, Duarte, Lilianne, MD, Madreperla, Steven, MD, Gonder, John, MD, Kapik, Barry, BS, Billman, Kathleen, BS, Kane, Frances E., PhD

“…Objective To assess the efficacy and safety of intravitreal inserts releasing 0.2 μg/day (low dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in…”
Get full text

PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular Degeneration by Peterson, Sheri L, Krishnan, Anitha, Patel, Diyan, Khanehzar, Ali, Lad, Amit, Shaughnessy, Jutamas, Ram, Sanjay, Callanan, David, Kunimoto, Derek, Genead, Mohamed A, Tolentino, Michael J

“…The alternative pathway of the complement system is implicated in the etiology of age-related macular degeneration (AMD). Complement depletion with…”
Get full text

Sialic Acid Mimetic Microglial Sialic Acid-Binding Immunoglobulin-like Lectin Agonism: Potential to Restore Retinal Homeostasis and Regain Visual Function in Age-Related Macular Degeneration by Tolentino, Michael J, Tolentino, Andrew J, Tolentino, Elizabeth M, Krishnan, Anitha, Genead, Mohamed A

“…Age-related macular degeneration (AMD), a leading cause of visual loss and dysfunction worldwide, is a disease initiated by genetic polymorphisms that impair…”
Get full text

The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema by Do, Diana V., MD, Schmidt-Erfurth, Ursula, MD, Gonzalez, Victor H., MD, Gordon, Carmelina M., MD, Tolentino, Michael, MD, Berliner, Alyson J., MD, PhD, Vitti, Robert, MD, MBA, Rückert, Rene, MD, Sandbrink, Rupert, MD, PhD, Stein, David, BS, Yang, Ke, PhD, Beckmann, Karola, MSc, Heier, Jeff S., MD

“…Purpose To determine whether different doses and dosing regimens of intravitreal vascular endothelial growth factor (VEGF) Trap-Eye are superior to focal/grid…”
Get full text

Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2 by Campochiaro, Peter A., MD, Sophie, Raafay, MD, Tolentino, Michael, MD, Miller, Daniel M., MD, PhD, Browning, David, MD, Boyer, David S., MD, Heier, Jeffrey S., MD, Gambino, Laura, BS, Withers, Barbara, PhD, Brigell, Mitchell, PhD, Peters, Kevin, MD

“…Purpose AKB-9778 is a small-molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase (VE-PTP) that promotes Tie2 activation and…”
Get full text

Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials by Krishnan, Anitha, Callanan, David G, Sendra, Victor G, Lad, Amit, Christian, Sunny, Earla, Ravinder, Khanehzar, Ali, Tolentino, Andrew J, Vailoces, Valory Anne Sarmiento, Greene, Michelle K, Scott, Christopher J, Kunimoto, Derek Y, Hassan, Tarek S, Genead, Mohamed A, Tolentino, Michael J

“…An inflammation-resolving polysialic acid-decorated PLGA nanoparticle (PolySia-NP) has been developed to treat geographic atrophy/age-related macular…”
Get full text

PolySialic acid-nanoparticles inhibit macrophage mediated inflammation through Siglec agonism: a potential treatment for age related macular degeneration by Krishnan, Anitha, Sendra, Victor G, Patel, Diyan, Lad, Amit, Greene, Michelle K, Smyth, Peter, Gallaher, Samantha A, Herron, Úna M, Scott, Christopher J, Genead, Mohamed, Tolentino, Michael

“…Age-related macular degeneration (AMD) is a chronic, progressive retinal disease characterized by an inflammatory response mediated by activated macrophages…”
Get full text

Safety of Intravitreal Ocriplasmin for Focal Vitreomacular Adhesion in Patients with Exudative Age-Related Macular Degeneration by Novack, Roger L., MD, PhD, Staurenghi, Giovanni, MD, Girach, Aniz, MD, Narendran, Nirodhini, MD, Tolentino, Michael, MD

“…Purpose The evaluation of the safety and preliminary efficacy of 125 μg ocriplasmin intravitreal injection in patients with focal vitreomacular adhesion (VMA)…”
Get full text

SCORE Study Report #11: Incidences of Neovascular Events in Eyes with Retinal Vein Occlusion by CHAN, Clement K, IP, Michael S, VANVELDHUISEN, Paul C, ODEN, Neal L, SCOTT, Ingrid U, TOLENTINO, Michael J, BLODI, Barbara A

“…To investigate in The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study: (1) incidences of neovascular events and retinal capillary…”
Get full text

Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model by Reich, Samuel J, Fosnot, Joshua, Kuroki, Akiko, Tang, Waixing, Yang, Xiangyang, Maguire, Albert M, Bennett, Jean, Tolentino, Michael J

“…RNA interference mediated by small interfering RNAs (siRNAs) is a powerful technology allowing the silencing of mamalian genes with great specificity and…”
Get full text

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate by Tolentino, Michael J, Mcleod, D.Scott, Taomoto, Makoto, Otsuji, Tsuyoshi, Adamis, Anthony P, Lutty, Gerard A

“…PURPOSE: Vascular endothelial growth factor (VEGF) is a potent ischemia-upregulated angiogenic protein that has been implicated in diabetic retinopathy…”
Get full text

Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization by Tolentino, Michael J, Brucker, Alexander J, Fosnot, Joshua, Ying, Gui-Shuang, Wu, I-Hui, Malik, Gulraiz, Wan, Shanhong, Reich, Samuel J

“…To determine the safety and efficacy of small interfering RNA (siRNA) directed against vascular endothelial growth factor (VEGF) in a nonhuman primate model of…”
Get full text

Inhibition of Retinal Neovascularization by Intraocular Viral-Mediated Delivery of Anti-angiogenic Agents by Auricchio, Alberto, Behling, Kathryn C., Maguire, Albert M., O'Connor, Erin E., Bennett, Jean, Wilson, James M., Tolentino, Michael J.

“…Neovascularization characterizes diabetic retinopathy and choroidal neovascularization associated with age-related macular degeneration, the most common causes…”
Get full text

Systemic rapamycin inhibits retinal and choroidal neovascularization in mice by Dejneka, Nadine S, Kuroki, Akiko M, Fosnot, Joshua, Tang, Waixing, Tolentino, Michael J, Bennett, Jean

“…Rapamycin exhibits significant antitumor/antiangiogenic activity that is coupled with a decrease in vascular endothelial growth factor (VEGF) production and a…”
Get full text

Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye by Auricchio, Alberto, Rivera, Victor M, Clackson, Tim, O'Connor, Erin E, Maguire, Albert M, Tolentino, Michael J, Bennett, Jean, Wilson, James M

“…The control, over time and space, of the levels of therapeutic proteins is crucial for successful retinal gene therapy. We tested the ability of…”
Get full text